KRAS and cancer: To illustrate, MSI positive stage II and III patients with double wild-type cancers had a 5-year cancer-specific survival of 93% (95% CI 84–100%); while, patients with cancers harboring mutations in either BRAF or KRAS had a 5-year cancer-specific survival of 76% (95% CI 67–85%) [15].